30/10/2020 18:00
EQS-Adhoc: Achiko AG Completes Capital Increase
INFORMATION REGLEMENTEE

EQS Group-Ad-hoc: Achiko AG / Key word(s): Capital Increase
Achiko AG Completes Capital Increase

30-Oct-2020 / 18:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.



Achiko AG Completes Capital Increase


Zurich, 30 October 2020 - Achiko AG (SWX:ACHI, ISIN CH0522213468) announces that following the financing round communicated on the 29th July 2020, its share capital recorded in the commercial register has been increased by 13,165,476 shares to 102,797,618 shares. The new shares have been issued out of the existing authorized capital and will be used towards settling existing commitments and to support the updated strategy of the company.

About Achiko AG
Headquartered in Switzerland, with a global market focus, Achiko AG (SWX:ACHI, ISIN CH0522213468) is an entrepreneurial platform company, utilising the knowledge and experience of its people and key technologies to enable transformation in various industries.


Through innovations in technology along with the company's unique operating footprint from Europe to Asia, Achiko seeks to transform markets and bring exceptional value to its customers, people, and shareholders. Achiko supports innovations in healthcare through its Teman Sehat ("Health Buddy") ecosystem and a novel saliva based Covid-19 testing technology, codenamed "Gumnuts", being developed with Regenacellx.sl.


Investor Relations & Press Contacts:

Investor Relations
ACHIKO AG

Investor Relations
E: ir@achiko.com


Press Contact Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Press Contact Germany and Austria
Axel Mühlhaus / Dr Sönke Knop
edicto GmbH
E: achiko@edicto.de
T: +49 69 90 55 05-51


Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.




End of ad hoc announcement
Language: English
Company: Achiko AG
Lavaterstrasse 66
8002 Zurich
Switzerland
E-mail: ir@achiko.com
Internet: https://www.achiko.com/
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1144418

 
End of Announcement EQS Group News Service

1144418  30-Oct-2020 CET/CEST


fncls.ssp?fn=show_t_gif&application_id=1144418&application_name=news&site_id=symex




EQS Group-Ad-hoc: Achiko AG / Key word(s): Capital Increase


Achiko AG Completes Capital Increase


30-Oct-2020 / 18:00 CET/CEST


Release of an ad hoc announcement pursuant to Art. 53 KR


The issuer is solely responsible for the content of this announcement.




Achiko AG Completes Capital Increase



Zurich, 30 October 2020 - Achiko AG (SWX:ACHI, ISIN CH0522213468) announces that following the financing round communicated on the 29th July 2020, its share capital recorded in the commercial register has been increased by 13,165,476 shares to 102,797,618 shares. The new shares have been issued out of the existing authorized capital and will be used towards settling existing commitments and to support the updated strategy of the company.

About Achiko AG

Headquartered in Switzerland, with a global market focus, Achiko AG (SWX:ACHI, ISIN CH0522213468) is an entrepreneurial platform company, utilising the knowledge and experience of its people and key technologies to enable transformation in various industries.



Through innovations in technology along with the company's unique operating footprint from Europe to Asia, Achiko seeks to transform markets and bring exceptional value to its customers, people, and shareholders. Achiko supports innovations in healthcare through its Teman Sehat (\"Health Buddy\") ecosystem and a novel saliva based Covid-19 testing technology, codenamed \"Gumnuts\", being developed with Regenacellx.sl.



Investor Relations & Press Contacts:

Investor Relations

ACHIKO AG


Investor Relations

E: ir@achiko.com



Press Contact Switzerland

Marcus Balogh

Farner Consulting Ltd.

E: achiko@farner.ch

T: +41 44 266 67 67

Press Contact Germany and Austria

Axel Mühlhaus / Dr Sönke Knop

edicto GmbH

E: achiko@edicto.de

T: +49 69 90 55 05-51



Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.






End of ad hoc announcement




















Language: English
Company: Achiko AG

Lavaterstrasse 66

8002 Zurich

Switzerland
E-mail: ir@achiko.com
Internet: https://www.achiko.com/
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1144418





 
End of Announcement EQS Group News Service



1144418  30-Oct-2020 CET/CEST



\"fncls.ssp?fn=show_t_gif&application_id=1144418&application_name=news&site_id=symex\"